Combination immunotherapy treatment effective before lung cancer...
Combination immunotherapy with the anti-PD-L1 monoclonal antibody durvalumab and other novel agents outperforms durvalumab alone in...
MD Anderson and Community Health Network announce...
The University of Texas MD Anderson Cancer Center and Indianapolis-based Community Health Network today announced a partnership...
MD Anderson receives over $10 million from Break Through...
The University of Texas MD Anderson Cancer Center was awarded more than $10 million in grants to support collaborative research teams...
Vitamin E can boost immunotherapy responses by reinvigorating...
Combining a retrospective analysis of clinical records with in-depth laboratory studies, researchers at The University of Texas MD...
MD Anderson Research Highlights for April 13, 2022
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recently published studies in basic,...
New platform optimizes selection of combination cancer...
Abstract: LB119
Researchers at The University of Texas MD Anderson Cancer Center have developed a new bioinformatics platform that...
Therapies targeting DNA damage response show promising...
NEW ORLEANS ― Results from early-stage clinical trials show two drugs that target the DNA damage response (DDR) pathway in cancers —...
NK cells combined with bispecific antibody showed strong...
Abstract: CT003
Researchers from The University of Texas MD Anderson Cancer Center showed that natural killer (NK) cells derived...
MD Anderson Research Highlights: AACR 2022 Special Edition
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and...
Lee Ellis honored by AACR for contributions to education...
The American Association for Cancer Research (AACR) has honored Lee Ellis, M.D., professor of Colon and Rectal Surgery at The...